Company: CDT
Filing Date: 2025-02-06
Form Type: S-8
Source: 0001493152-25-005249
Chunk: 1

Company: CDT Equity Inc.
Filing Date: 2025-02-06
Form: S-8
Chunk 1
---
PLANATORY NOTE</div>

An amendment (the “Amendment”) to the second amended and restated certificate of incorporation of Conduit Pharmaceuticals Inc. (the “Registrant”) was filed with the Secretary of State of the State of Delaware to effect a 1-for-100 reverse split (the “Reverse Stock Split”) of the Registrant’s issued and outstanding common stock, with an effective time of 5:00 p.m. Eastern Time on January 24, 2025. As a result of the Reverse Stock Split, every 100 shares of the Registrant’s common stock, either issued or outstanding, immediately prior to the filing and effectiveness of the Amendment, was automatically combined and converted (without any further act) into one share of fully paid and nonassessable share of common stock. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders of record who would have otherwise been entitled to receive a fractional share of common stock received a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing price per share of the common stock (as adjusted for the Reverse Stock Split) on The Nasdaq Global Market on January 24, 2025.Unless otherwise indicated, all share numbers herein, including common stock registered hereunder and registered under prior registration statements, give effect to the Reverse Stock Split.

This registration statement on Form S-8 registers 69,240 additional shares of common stock of the Registrant may be issued under the Conduit Pharmaceuticals Inc. 2023 Stock Incentive Plan (the “2023 Plan”). The number of shares of common stock available for issuance under the 2023 Plan is subject to an automatic annual increase on the first day of each fiscal year commencing January 1, 2024 and continuing annually on each anniversary thereof through (and including) January 1, 2033, equal to the lesser of (A) 5% of the shares of common stock outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares of common stock as determined by the Registrant’s board of directors or its Compensation Committee (the “Plan Evergreen Provision”). Pursuant to the Plan Evergreen Provision, the number of shares of common stock available for issuance under the 2023 Plan was increased by 69,240 shares of common stock effective January 1, 2025. This registration statement registers the additional shares of common stock available for issuance under the